Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer | Journal of Clinical Oncology | 2003 | 1.4K |
Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development | Proceedings of the National Academy of Sciences of the United States of America | 2007 | 1.1K |
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | New England Journal of Medicine | 2017 | 1.1K |
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 | Journal of Clinical Oncology | 2008 | 1K |
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers | Journal of the National Cancer Institute | 2006 | 713 |
Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline | International Journal of Radiation Oncology Biology Physics | 2011 | 614 |
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression | Journal of Clinical Oncology | 2008 | 578 |
Platelet activity of high-dose factor VIIa is independent of tissue factor | British Journal of Haematology | 1997 | 509 |
Thresholds for thermal damage to normal tissues: an update | International Journal of Hyperthermia | 2011 | 419 |
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes | Journal of Clinical Oncology | 2002 | 417 |
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal | International Journal of Radiation Oncology Biology Physics | 2013 | 396 |
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial | Journal of Clinical Oncology | 2003 | 389 |
Dicer1 functions as a haploinsufficient tumor suppressor | Genes and Development | 2009 | 353 |
American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy | Brachytherapy | 2012 | 342 |
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma | Neuro-Oncology | 2010 | 338 |
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas | International Journal of Radiation Oncology Biology Physics | 2009 | 320 |
A review of cancer immunotherapy toxicity | Ca-A Cancer Journal for Clinicians | 2020 | 304 |
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history | Journal of the National Cancer Institute | 1997 | 299 |
Primary tumor location as a prognostic factor in metastatic colorectal cancer | Journal of the National Cancer Institute | 2015 | 298 |
Animal models for medical countermeasures to radiation exposure | Radiation Research | 2010 | 283 |
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays | Journal of Immunological Methods | 2002 | 272 |
The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin | Proceedings of the National Academy of Sciences of the United States of America | 1997 | 258 |
Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) | Annals of Surgery | 2016 | 257 |
Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial | Annals of Surgery | 2014 | 244 |
Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease | Cancer | 2012 | 236 |